Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Successful Treatment of High-Risk and Refractory Acute Myeloid Leukemia with haploidentical Stem Cell Transplantation Plus NK cell therapy

Lutz Uharek, MD, Birte Friedrichs, MD, Axel Nogai, MD, Chiara Gentilini, MD, Nadezda Basara, MD, Dietger Niederwieser, MD, Eckhard Thiel, MD

Blood (2010) 116 (21): 2370.

https://doi.org/10.1182/blood.V116.21.2370.2370

Published: 2010

Journal Articles

NK-Cell Recovery and Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation Using Either CD34 Selected Grafts and Adoptive NK-Cell Transfer or CD3/CD19 Depleted Grafts: Comparison of Two Strategies for NK Cell Based Immunotherapy.

Chiara Gentilini, MD, Matthias Haegele, Arne Muessig, MD, Axel Nogai, MD, Constanze Kliem, MD, Kristina Bartsch, MD, Nadezda Bazara, Wichard Vogel, MD, Christoph Faul, MD, Lothar Kanz, MD, Eckhard Thiel, Dietger W. Niederwieser, Lutz Uharek, Wolfgang A. Bethge, MD

Blood (2007) 110 (11): 2988.

https://doi.org/10.1182/blood.V110.11.2988.2988

Published: 2007

Journal Articles

Patients Receiving IL-2 Activated Donor NK Cells Show Lower Incidence of Severe GvHD after Haploidentical SCT.

Chiara Gentilini, MD, Urte Hilbers, Volker Huppert, Christoph Loddenkemper, MD, Arne Müßig, MD, Constanze Kliem, MD, Thoralf Lange, MD, Nadezda Basara, Marcus Uhrberg, Eckhard Thiel, Dietger W. Niederwieser, Lutz Uharek

Blood (2007) 110 (11): 354.

https://doi.org/10.1182/blood.V110.11.354.354

Published: 2007

Journal Articles

Vaccination with the WT-1 126-134 Peptide in Patients with Acute Myeloid Leukemia after Allogenic Stem Cell Transplantation.

Chiara Gentilini, MD, Anne Letsch, MD, Annemarie Asemissen, MD, Arne Muessig, MD, Katrin Rieger, MD, Carmen Scheibenbogen, Eckhard Thiel, Lutz Uharek

Blood (2006) 108 (11): 3683.

https://doi.org/10.1182/blood.V108.11.3683.3683

Published: 2006

Journal Articles

An Immunogenic Peptide Derived from NM23-H2 Is Expressed on Bcr/abl + Cells.

Sabine Tschiedel, PhD, Annette Reinhardt, Chiara Gentilini, MD, Thomas Wölfel, Hans-Georg Rammensee, Dietger W. Niederwieser

Blood (2006) 108 (11): 3684.

https://doi.org/10.1182/blood.V108.11.3684.3684

Published: 2006

Journal Articles

Alemtuzumab but Not ATG Decreases Natural Killer (NK) Cell Activity towards Tumor Targets in the Early Phase after Allogeneic Stem Cell Transplantation.

Olaf Penack, MD, Lars Fischer, MD, Andrea Stroux, Chiara Gentilini, MD, Axel Nogai, MD, Arne Muessig, MD, Susanne Ganepola, MD, Eckhard Thiel, MD, Lutz Uharek, MD

Blood (2006) 108 (11): 2869.

https://doi.org/10.1182/blood.V108.11.2869.2869

Published: 2006

Journal Articles

High Anti-Tumor Activity of Natural Killer Cells after Non-Myeloablative Conditioning and Allogeneic Stem Cell Transplantation.

Lars Fischer, MD, Olaf Penack, MD, Andrea Stroux, Chiara Gentilini, MD, Eckhard Thiel, Lutz Uharek

Blood (2006) 108 (11): 5146.

https://doi.org/10.1182/blood.V108.11.5146.5146

Published: 2006

Journal Articles

Analysis of Factors Influencing Natural Killer (NK) Cell Activity during the Early Phase after Allogeneic Stem Cell Transplantation (SCT).

Lars Fischer, MD, Olaf Penack, MD, Chiara Gentilini, MD, Eckhard Thiel, MD, Uharek Lutz, MD

Blood (2005) 106 (11): 2192.

https://doi.org/10.1182/blood.V106.11.2192.2192

Published: 2005

Journal Articles

Treatment of Myeloid and Lymphoid Malignancies with Highly Purified Alloreactive CD56+CD3− NK-Cells and Haploidentical Stem Cell Transplantation: Promising Results of a Phase I Study.

Chiara Gentilini, MD, Urte Hilbers, Goetz Hartung, MD, Thoralf Lange, MD, Constanze Kliem, MD, Ute Hegenbart, MD, Mathias Zeis, MD, Volker Huppert, Bertram Glass, Marcus Uhrberg, Norbert Schmitz, Eckhard Thiel, Dietger W. Niederwieser, Lutz Uharek

Blood (2005) 106 (11): 2906.

https://doi.org/10.1182/blood.V106.11.2906.2906

Published: 2005

Journal Articles

Preemptive Transfer of GMP-Grade CD8-Depleted Donor Lymphocytes after T-Cell Depleted Reduced-Intensity Transplantation.

Ralf G. Meyer, MD, Cedrik M. Britten, MD, Abdo Konur, PhD, Klaus Bender, PhD, Daniela Wehler, MD, Udo Hartwig, PhD, Thomas C. Wehler, MD, Chiara Gentilini, MD, Lutz Uharek, MD, Christoph Huber, MD, Karin Kolbe, MD, Wolfgang Herr, MD

Blood (2005) 106 (11): 297.

https://doi.org/10.1182/blood.V106.11.297.297

Published: 2005

Journal Articles

Quantification and Characterization of Peripheral Blood Natural Killer (NK) Cells Mediating Rituximab and Alemtuzumab Dependent Cytotoxicity.

Olaf Penack, MD, Lars Fischer, MD, Chiara Gentilini, MD, Anne M. Asemissen, MD, Carmen Scheibenbogen, MD, Eckhard Thiel, MD, Lutz Uharek, MD

Blood (2005) 106 (11): 2808.

https://doi.org/10.1182/blood.V106.11.2808.2808

Published: 2005

Journal Articles

WT1-Specific T Cell Responses Are Frequent after Allogeneic Stem Cell Transplantation for Acute and Chronic Myeloid Leukemia.

Chiara Gentilini, MD, Urte Hilbers, Susanne Ganepola, MD, Carmen Scheibenbogen, Katy Freyberg, Dietger W. Niederwieser, Eckhard Thiel, Lutz Uharek

Blood (2005) 106 (11): 598.

https://doi.org/10.1182/blood.V106.11.598.598

Published: 2005

Journal Articles

Mesenchymal Stem Cells of Patients with Chronic Myeloid Leukemia Are Philadelphia Negative.

Chiara Gentilini, MD, Kathrin H. Al-Ali, MD, Annette Reinhardt, Kristina Bartsch, Toralf Lange, MD, Dietger W. Niederwieser

Blood (2004) 104 (11): 4683.

https://doi.org/10.1182/blood.V104.11.4683.4683

Published: 2004

NARROW

Successful Treatment of High-Risk and Refractory Acute Myeloid Leukemia with haploidentical Stem Cell Transplantation Plus NK cell therapy

NK-Cell Recovery and Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation Using Either CD34 Selected Grafts and Adoptive NK-Cell Transfer or CD3/CD19 Depleted Grafts: Comparison of Two Strategies for NK Cell Based Immunotherapy.

Patients Receiving IL-2 Activated Donor NK Cells Show Lower Incidence of Severe GvHD after Haploidentical SCT.

Vaccination with the WT-1 126-134 Peptide in Patients with Acute Myeloid Leukemia after Allogenic Stem Cell Transplantation.

An Immunogenic Peptide Derived from NM23-H2 Is Expressed on Bcr/abl + Cells.

Alemtuzumab but Not ATG Decreases Natural Killer (NK) Cell Activity towards Tumor Targets in the Early Phase after Allogeneic Stem Cell Transplantation.

High Anti-Tumor Activity of Natural Killer Cells after Non-Myeloablative Conditioning and Allogeneic Stem Cell Transplantation.

Analysis of Factors Influencing Natural Killer (NK) Cell Activity during the Early Phase after Allogeneic Stem Cell Transplantation (SCT).

Treatment of Myeloid and Lymphoid Malignancies with Highly Purified Alloreactive CD56+CD3− NK-Cells and Haploidentical Stem Cell Transplantation: Promising Results of a Phase I Study.

Preemptive Transfer of GMP-Grade CD8-Depleted Donor Lymphocytes after T-Cell Depleted Reduced-Intensity Transplantation.

Quantification and Characterization of Peripheral Blood Natural Killer (NK) Cells Mediating Rituximab and Alemtuzumab Dependent Cytotoxicity.

WT1-Specific T Cell Responses Are Frequent after Allogeneic Stem Cell Transplantation for Acute and Chronic Myeloid Leukemia.

Mesenchymal Stem Cells of Patients with Chronic Myeloid Leukemia Are Philadelphia Negative.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only